These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 26245646)

  • 1. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
    Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
    Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review.
    Watson C; Tallentire CW; Ramage JK; Srirajaskanthan R; Leeuwenkamp OR; Fountain D
    World J Gastroenterol; 2020 Jul; 26(25):3686-3711. PubMed ID: 32742136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours.
    Martini C; Gamper EM; Wintner L; Nilica B; Sperner-Unterweger B; Holzner B; Virgolini I
    Health Qual Life Outcomes; 2016 Sep; 14(1):127. PubMed ID: 27614762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours - an analysis based on the CLARINET study.
    Meng Y; McCarthy G; Berthon A; Dinet J
    Health Qual Life Outcomes; 2017 Jun; 15(1):131. PubMed ID: 28662673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Cloyd JM; Konda B; Shah MH; Pawlik TM
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
    Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
    Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Phan AT; Kunz PL; Reidy-Lagunes DL
    Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Scoville SD; Cloyd JM; Pawlik TM
    Expert Opin Pharmacother; 2020 Feb; 21(2):183-191. PubMed ID: 31760823
    [No Abstract]   [Full Text] [Related]  

  • 9. Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine.
    Martini C; Buxbaum S; Rodrigues M; Nilica B; Scarpa L; Holzner B; Virgolini I; Gamper EM
    J Nucl Med; 2018 Oct; 59(10):1566-1573. PubMed ID: 30042164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
    Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion.
    Yoo C; Oh CR; Kim ST; Bae WK; Choi HJ; Oh DY; Lee MA; Ryoo BY
    Cancer Res Treat; 2021 Apr; 53(2):291-300. PubMed ID: 33421978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Strosberg JR
    CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
    Ronde EM; Heidsma CM; Eskes AM; Schopman JE; Nieveen van Dijkum EJM
    Eur J Cancer Care (Engl); 2021 Nov; 30(6):e13504. PubMed ID: 34462979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applying Reflective Multicriteria Decision Analysis (MCDA) to Patient-Clinician Shared Decision-Making on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the Spanish Context.
    Wagner M; Samaha D; Cuervo J; Patel H; Martinez M; O'Neil WM; Jimenez-Fonseca P
    Adv Ther; 2018 Aug; 35(8):1215-1231. PubMed ID: 29987525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update in the management of gastroenteropancreatic neuroendocrine tumors.
    Sedlack AJH; Varghese DG; Naimian A; Yazdian Anari P; Bodei L; Hallet J; Riechelmann RP; Halfdanarson T; Capdevilla J; Del Rivero J
    Cancer; 2024 Sep; 130(18):3090-3105. PubMed ID: 39012928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on gastroenteropancreatic neuroendocrine tumors.
    Cives M; Strosberg J
    Oncology (Williston Park); 2014 Sep; 28(9):749-56, 758. PubMed ID: 25224471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors.
    Riff BP; Yang YX; Soulen MC; Pryma DA; Bennett B; Wild D; Nicolas G; Teitelbaum UR; Metz DC
    Clin Nucl Med; 2015 Nov; 40(11):845-50. PubMed ID: 26284763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours.
    Lewis AR; Wang X; Magdalani L; D'Arienzo P; Bashir C; Mansoor W; Hubner R; Valle JW; McNamara MG
    World J Gastroenterol; 2018 Feb; 24(6):671-679. PubMed ID: 29456406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
    Jin XF; Spampatti MP; Spitzweg C; Auernhammer CJ
    Rev Endocr Metab Disord; 2018 Jun; 19(2):145-158. PubMed ID: 29464446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.